TL;DR
- •SSRIs (Lexapro, Zoloft, Prozac) block serotonin reuptake only; SNRIs (Effexor, Cymbalta) block both serotonin AND norepinephrine reuptake.
- •Efficacy in depression is comparable between classes — about 50-60% response either way.
- •SNRIs have better evidence in chronic pain (especially fibromyalgia and neuropathic pain) because of the norepinephrine effect.
- •SSRIs generally have a cleaner side-effect profile; SNRIs more commonly cause sweating, blood pressure elevation, and harder discontinuation syndromes.
- •First-line for new-onset depression is usually an SSRI; switching to an SNRI is common after SSRI non-response.
- •For patients who've tried both classes without adequate response, the next step is typically a mechanism-switch (ketamine, NDRI, augmentation) rather than another serotonin-focused drug.
Side by side
SSRIs
Selective Serotonin Reuptake Inhibitors
Antidepressant class
What it treats
Major depression, Anxiety disorders, PTSD, OCD, PMDD
Mechanism
Block reuptake of serotonin at the serotonin transporter (SERT), gradually raising synaptic serotonin over weeks. Examples: Lexapro, Zoloft, Prozac, Celexa, Paxil.
Strengths
- •Generally cleaner side-effect profile than SNRIs
- •Better-tolerated discontinuation (with exceptions like Paxil)
- •Wider FDA approval list across psychiatric indications
- •Lower blood pressure / cardiovascular impact
Limitations
- •Sexual dysfunction (30-50%)
- •Emotional blunting reported by many patients
- •No benefit in pain conditions
- •4-8 weeks to evaluate response
SNRIs
Serotonin-Norepinephrine Reuptake Inhibitors
Antidepressant class
What it treats
Major depression, GAD, Chronic pain (fibromyalgia, diabetic neuropathy), PTSD (some)
Mechanism
Block reuptake of both serotonin AND norepinephrine. The added norepinephrine effect produces analgesic benefit in chronic pain conditions. Examples: Effexor, Cymbalta, Pristiq.
Strengths
- •FDA-approved for chronic pain conditions (Cymbalta: fibromyalgia, diabetic neuropathy)
- •Norepinephrine effect may help patients with fatigue, low motivation, anhedonia
- •Strong evidence in generalized anxiety
- •May work where multiple SSRIs failed (different receptor profile)
Limitations
- •Blood pressure elevation, sweating, dry mouth more common than SSRIs
- •Discontinuation syndrome harder than most SSRIs (especially Effexor)
- •Sexual dysfunction at similar rates to SSRIs
- •Same 4-8 week response window as SSRIs
Which one for your situation?
If:
First antidepressant ever, primary diagnosis depression or anxiety
Verdict:
SSRI — first-line; better-tolerated starting point
If:
Comorbid chronic pain (fibromyalgia, diabetic neuropathy, lower back pain)
Verdict:
SNRI — especially Cymbalta, with specific FDA pain indications
If:
Tried two SSRIs without response
Verdict:
SNRI is the standard next step — different receptor profile, ~30% additional response
If:
History of hypertension or cardiovascular disease
Verdict:
SSRI — SNRIs can raise BP, especially at higher doses
If:
Predominant symptom is fatigue/low motivation
Verdict:
SNRI or NDRI (Wellbutrin) — norepinephrine/dopamine effect helps where pure serotonin doesn't
If:
Already tried both classes without adequate response
Verdict:
Mechanism-switch — ketamine (NMDA/glutamate), TMS, or augmentation strategies
Where ketamine fits
After both an SSRI trial and an SNRI trial without adequate response, the patient meets the technical definition of treatment-resistant depression. Ketamine's NMDA/glutamate mechanism is entirely different from any serotonin/norepinephrine reuptake drug. Published response rates in treatment-resistant cases are 60-70% within hours of the first session.
SSRIs and SNRIs both require 4-8 weeks to evaluate response. Sublingual ketamine produces measurable response within hours of the first session.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Are SNRIs stronger than SSRIs?
Not in terms of antidepressant effect — efficacy in major depression is comparable per the Cipriani 2018 network meta-analysis. SNRIs have an additional benefit in chronic pain conditions because of the norepinephrine effect, which SSRIs don't share. "Stronger" depends on what you're measuring.
I failed an SSRI. Should I try another SSRI or jump to an SNRI?
Most clinicians try a class-switch (SSRI → SNRI) after one SSRI failure because the different receptor profile produces ~30% additional response. Trying a second SSRI works for only about 25-30% of patients. Some scenarios favor within-class switch (e.g., if side effects were the failure mode rather than non-response).
I've tried SSRIs and SNRIs. What's next?
Two failed antidepressant trials defines treatment-resistant depression. Standard next steps are mechanism-switch (NDRI like Wellbutrin, or NMDA antagonist like ketamine), augmentation (adding lithium or atypical antipsychotic), TMS (non-pharmacological), or ECT (severe cases). Ketamine specifically has the strongest evidence in the treatment-resistant subset and produces response within hours rather than weeks.
Can I take ketamine alongside my SSRI or SNRI?
In most cases, yes. Ketamine works through NMDA/glutamate signaling — a completely different mechanism from serotonin/norepinephrine reuptake. There's no requirement to taper off your antidepressant before starting ketamine. Your physician reviews your full medication list during consultation.
Which is harder to come off of — SSRIs or SNRIs?
SNRIs are generally harder to discontinue than SSRIs, especially Effexor (venlafaxine) which has a short half-life. Discontinuation syndrome can include flu-like symptoms, "brain zaps," dizziness, irritability. Among SSRIs, Paxil (paroxetine) is the hardest; Prozac (fluoxetine) is the easiest because of its long half-life. Always taper under physician supervision rather than stopping abruptly.
References
- Cipriani A et al. 2018, Lancet. Network meta-analysis ranked SSRIs and SNRIs in the same efficacy tier for major depression — both classes superior to placebo, similar to each other. PMID 29477251
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus statement on ketamine's rapid antidepressant effects across patients who have failed multiple antidepressant trials including SSRIs and SNRIs. PMID 28249076